IKT
Inhibikase Therapeutics, Inc.NASDAQHealthcare$1.80-0.56%ClosedMarket Cap: $127.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.02
P/S
0.00
EV/EBITDA
0.23
DCF Value
$1.41
FCF Yield
-22.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-46.9%
ROA
-26.6%
ROIC
-26.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-7.3M | $-12.7M | $-0.10 | — |
| FY 2025 | $0.00 | -Infinity% | $-45.9M | $-48.3M | $-0.49 | — |
| Q3 2025 | $0.00 | -Infinity% | $-13.3M | $-11.9M | $-0.13 | — |
| Q2 2025 | $0.00 | -Infinity% | $-10.8M | $-9.9M | $-0.11 | — |
| Q1 2025 | $0.00 | -Infinity% | $-14.6M | $-13.7M | $-0.15 | — |
| Q4 2024 | $0.00 | -Infinity% | $-12.9M | $-12.1M | $-0.17 | — |
| FY 2024 | $0.00 | -Infinity% | $-28.6M | $-27.5M | $-1.16 | — |
| Q3 2024 | $0.00 | -Infinity% | $-5.8M | $-5.8M | $-0.65 | — |
| Q2 2024 | $0.00 | -Infinity% | $-5.1M | $-5.0M | $-0.66 | — |
| Q1 2024 | $0.00 | -Infinity% | $-4.8M | $-4.6M | $-0.73 | — |
| Q4 2023 | $1.00 | -656700.0% | $-4.4M | $-4.2M | $-0.68 | — |
| FY 2023 | $260.5K | -5127.8% | $-20.1M | $-19.0M | $-3.57 | — |